Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells

Toxicology in Vitro

Volumn 40, Issue , 2017, Pages 272-279

  Carpi, Sara ^a   Fogli, Stefano ^a   Polini, Beatrice ^a   Montagnani, Valentina ^b   Podestà, Adriano ^a   Breschi, Maria Cristina ^a   Romanini, Antonella ^c   Stecca, Barbara ^b   Nieri, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Cannabinoid receptor type 1; Melanoma; Tumorigenic role

Indexed keywords

CANNABINOID 1 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA;

ARTICLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL MIGRATION; CELL VIABILITY; CLONOGENESIS; COLONY FORMING UNIT; CONTROLLED STUDY; EMBRYO; G1 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; GENETICS; MELANOMA; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, CANNABINOID, CB1;

EID: 85011349859     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2017.01.018     Document Type: Article

References (39)

1. Adinolfi, B., Romanini, A., Vanni, A., Martinotti, E., Chicca, A., Fogli, S., Nieri, P., Anticancer activity of anandamide in human cutaneous melanoma cells. Eur. J. Pharmacol. 718 (2013), 154–159, 10.1016/j.ejphar.2013.08.039.
2. Bardeesy, N., Kim, M., Xu, J., Kim, R.-S., Shen, Q., Bosenberg, M.W., Wong, W.H., Chin, L., Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol. Cell. Biol. 25 (2005), 4176–4188, 10.1128/MCB.25.10.4176-4188.2005.
3. Blázquez, C., Carracedo, A., Barrado, L., Real, P.J., Fernández-Luna, J.L., Velasco, G., Malumbres, M., Guzmán, M., Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20 (2006), 2633–2635, 10.1096/fj.06-6638fje.
4. Carpi, S., Fogli, S., Giannetti, A., Adinolfi, B., Tombelli, S., Da Pozzo, E., Vanni, A., Martinotti, E., Martini, C., Breschi, M.C., Pellegrino, M., Nieri, P., Baldini, F., Theranostic properties of a survivin-directed molecular beacon in human melanoma cells. PLoS ONE, 9, 2014, e114588, 10.1371/journal.pone.0114588.
5. Carpi, S., Fogli, S., Romanini, A., Pellegrino, M., Adinolfi, B., Podestà, A., Costa, B., Da Pozzo, E., Martini, C., Breschi, M.C., Nieri, P., AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. Anti-Cancer Drugs, 1, 2015, 10.1097/CAD.0000000000000246 (Publish Ahead of Print).
6. Chakravarti, B., Ravi, J., Ganju, R.K., Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget 5 (2014), 5852–5872, 10.18632/oncotarget.2233.
7. De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., Di Marzo, V., The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 8375–8380.
8. Di Marzo, V., The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 60 (2009), 77–84, 10.1016/j.phrs.2009.02.010.
9. Fogli, S., Nieri, P., Chicca, A., Adinolfi, B., Mariotti, V., Iacopetti, P., Breschi, M.C., Pellegrini, S., Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 580 (2006), 1733–1739, 10.1016/j.febslet.2006.02.024.
10. Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M., Maccarrone, M., Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog. Lipid Res. 52 (2013), 633–650, 10.1016/j.plipres.2013.05.004.
11. Glodde, N., Jakobs, M., Bald, T., Tüting, T., Gaffal, E., Differential role of cannabinoids in the pathogenesis of skin cancer. Life Sci. 138 (2015), 35–40, 10.1016/j.lfs.2015.04.003.
12. Grimaldi, C., Pisanti, S., Laezza, C., Malfitano, A.M., Santoro, A., Vitale, M., Caruso, M.G., Notarnicola, M., Iacuzzo, I., Portella, G., Di Marzo, V., Bifulco, M., Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res. 312 (2006), 363–373, 10.1016/j.yexcr.2005.10.024.
13. Guindon, J., Hohmann, A.G., The endocannabinoid system and cancer: therapeutic implication. Br. J. Pharmacol. 163 (2011), 1447–1463, 10.1111/j.1476-5381.2011.01327.x.
14. Hillard, C.J., Endocannabinoids and the endocrine system in health and disease. Handb. Exp. Pharmacol. 231 (2015), 317–339, 10.1007/978-3-319-20825-1_11.
15. Jeong, W.-I., Osei-Hyiaman, D., Park, O., Liu, J., Bátkai, S., Mukhopadhyay, P., Horiguchi, N., Harvey-White, J., Marsicano, G., Lutz, B., Gao, B., Kunos, G., Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 7 (2008), 227–235, 10.1016/j.cmet.2007.12.007.
16. Kenessey, I., Bánki, B., Márk, A., Varga, N., Tóvári, J., Ladányi, A., Rásó, E., Tímár, J., Revisiting CB1 receptor as drug target in human melanoma. Pathol. Oncol. Res. 18 (2012), 857–866, 10.1007/s12253-012-9515-y.
17. Kokona, D., Thermos, K., Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: involvement of PI3K/Akt and MEK/ERK signaling pathways. Exp. Eye Res. 136 (2015), 45–58, 10.1016/j.exer.2015.05.007.
18. Laezza, C., Malfitano, A.M., Proto, M.C., Esposito, I., Gazzerro, P., Formisano, P., Pisanti, S., Santoro, A., Caruso, M.G., Bifulco, M., Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. Endocr. Relat. Cancer 17 (2010), 495–503, 10.1677/ERC-10-0009.
19. Maccarrone, M., Bab, I., Bíró, T., Cabral, G.A., Dey, S.K., Di Marzo, V., Konje, J.C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K.A., Zimmer, A., Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36 (2015), 277–296, 10.1016/j.tips.2015.02.008.
20. Minocci, D., Massei, J., Martino, A., Milianti, M., Piz, L., Di Bello, D., Sbrana, A., Martinotti, E., Rossi, A.M., Nieri, P., Genetic association between bipolar disorder and 524A > C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. J. Affect. Disord. 134 (2011), 427–430, 10.1016/j.jad.2011.05.023.
21. Mukhopadhyay, B., Liu, J., Osei-Hyiaman, D., Godlewski, G., Mukhopadhyay, P., Wang, L., Jeong, W.-I., Gao, B., Duester, G., Mackie, K., Kojima, S., Kunos, G., Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J. Biol. Chem. 285 (2010), 19002–19011, 10.1074/jbc.M109.068460.
22. Nieri, P., Greco, R., Adinolfi, B., Breschi, M.C., Martinotti, E., Nannetti, C., Podestà, A., CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. Naunyn Schmiedeberg's Arch. Pharmacol. 368 (2003), 352–359, 10.1007/s00210-003-0831-3.
23. Nieri, P., Martinotti, E., Testai, L., Adinolfi, B., Calderone, V., Breschi, M.C., R +-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors. Eur. J. Pharmacol. 459 (2003), 75–81.
24. Ozaita, A., Puighermanal, E., Maldonado, R., Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J. Neurochem. 102 (2007), 1105–1114, 10.1111/j.1471-4159.2007.04642.x.
25. Pertwee, R.G., Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. CMC 17 (2010), 1360–1381.
26. Pisanti, S., Picardi, P., D'Alessandro, A., Laezza, C., Bifulco, M., The endocannabinoid signaling system in cancer. Trends Pharmacol. Sci. 34 (2013), 273–282, 10.1016/j.tips.2013.03.003.
27. Pisanti, S., Picardi, P., Pallottini, V., Martini, C., Petrosino, S., Proto, M.C., Vitale, M., Laezza, C., Gazzerro, P., Di Marzo, V., Bifulco, M., Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration. J. Cell. Physiol. 230 (2015), 2905–2914, 10.1002/jcp.24959.
28. Pucci, M., Pasquariello, N., Battista, N., Di Tommaso, M., Rapino, C., Fezza, F., Zuccolo, M., Jourdain, R., Finazzi Agrò, A., Breton, L., Maccarrone, M., Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. J. Biol. Chem. 287 (2012), 15466–15478, 10.1074/jbc.M111.314880.
29. Santini, R., Pietrobono, S., Pandolfi, S., Montagnani, V., D'Amico, M., Penachioni, J.Y., Vinci, M.C., Borgognoni, L., Stecca, B., SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene 33 (2014), 4697–4708, 10.1038/onc.2014.71.
30. Sarnataro, D., Pisanti, S., Santoro, A., Gazzerro, P., Malfitano, A.M., Laezza, C., Bifulco, M., The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol. Pharmacol. 70 (2006), 1298–1306, 10.1124/mol.106.025601.
31. Scuderi, M.R., Cantarella, G., Scollo, M., Lempereur, L., Palumbo, M., Saccani-Jotti, G., Bernardini, R., The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. Cancer Lett. 310 (2011), 240–249, 10.1016/j.canlet.2011.07.008.
32. Shakhova, O., Neural crest stem cells in melanoma development. Curr. Opin. Oncol. 26 (2014), 215–221, 10.1097/CCO.0000000000000046.
33. Spagnolo, F., Picasso, V., Lambertini, M., Ottaviano, V., Dozin, B., Queirolo, P., Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review. Cancer Treat. Rev. 45 (2016), 38–45, 10.1016/j.ctrv.2016.03.003.
34. Stecca, B., Ruiz i Altaba, A., A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J. 28 (2009), 663–676, 10.1038/emboj.2009.16.
35. Torii, S., Yamamoto, T., Tsuchiya, Y., Nishida, E., ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 97 (2006), 697–702, 10.1111/j.1349-7006.2006.00244.x.
36. Velasco, G., Sánchez, C., Guzmán, M., Endocannabinoids and cancer. Handb. Exp. Pharmacol. 231 (2015), 449–472, 10.1007/978-3-319-20825-1_16.
37. Zheng, D., Bode, A.M., Zhao, Q., Cho, Y.-Y., Zhu, F., Ma, W.-Y., Dong, Z., The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res. 68 (2008), 3992–3998, 10.1158/0008-5472.CAN-07-6594.
38. Zhou, X.P., Gimm, O., Hampel, H., Niemann, T., Walker, M.J., Eng, C., Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157 (2000), 1123–1128, 10.1016/S0002-9440(10)64627-5.
39. Zhou, Y., Falenta, K., Lalli, G., Endocannabinoid signalling in neuronal migration. Int. J. Biochem. Cell Biol. 47 (2014), 104–108, 10.1016/j.biocel.2013.12.007.